CRP has been used as an independent prognostic indicator in studies of a variety of diseases, including multiple myeloma, lymphoma, melanoma and ovarian, renal, pancreatic and gastrointestinal tumors (32). This evidence concerns the gene CRP and digestive system neoplasm.